Is low‑dose atropine eye drop therapy appropriate for controlling myopia progression in a growing child or adolescent with documented worsening refractive error?

Low-Dose Atropine for Myopia Control in Children

Low-dose atropine eye drops are appropriate and effective for controlling myopia progression in children and adolescents with documented worsening refractive error, with 0.05% concentration offering the optimal balance between efficacy and tolerability.

Recommendation Algorithm

Initial Assessment

For any child aged 6-12 years with progressive myopia (≥-0.50 D annual progression), consider low-dose atropine as first-line pharmacologic therapy 1.

Concentration Selection

Start with atropine 0.05% as the optimal initial concentration 1:

• The LAMP study demonstrated that 0.05% atropine had double the efficacy of 0.01% in slowing myopia progression over 2 years 1
• Benefits continue into year 3 compared with stopping treatment 1
• Real-world evidence from Chinese children confirms 0.025-0.05% offers superior SE control compared to 0.01% 2

Alternative: Consider 0.01% for:

• Children under 6 years (though evidence is primarily for ages 6-12)
• Concerns about photophobia or accommodation effects
• Initial trial in cautious families

Expected Outcomes

Efficacy data:

• Mean reduction in myopia progression: approximately 0.33 D over 2 years compared to placebo 3
• Axial length elongation reduced by approximately 0.14 mm 3
• 0.05% concentration shows mean SE progression of only -0.27 D at 12 months 2

Important Nuance: Geographic Variation

Critical caveat: One high-quality US-based RCT found no benefit of 0.01% atropine versus placebo in American children 4. However:

• This contradicts multiple Asian studies and the recent UK CHAMP trial 3
• The UK CHAMP trial (2026) demonstrated significant efficacy in predominantly white children 3
• Current AAO guidelines support use across populations 1

Clinical interpretation: The preponderance of evidence, including the most recent UK data, supports efficacy across ethnicities. The single negative US trial used only 0.01% concentration, which may be suboptimal.

Administration Protocol

• Dosing: One drop nightly to both eyes 1
• Duration: Minimum 2 years of continuous treatment for sustained benefit 1
• Monitoring: Every 6 months for refraction, axial length, and side effects

Safety Profile

Common but manageable effects:

• Pupil dilation (mean increase 0.36 mm with 0.01%) 3
• Photophobia and glare (minimal with concentrations ≤0.05%) 1
• Accommodation reduction (rarely requires bifocals at low doses) 1

Serious concerns to monitor:

• Rare cases of acquired esotropia or convergence excess, particularly with dose escalation 5
• Monitor near point of convergence and binocular function at each visit 5
• Most alignment issues resolve after discontinuation 5

Reassuring long-term data:

• No significant retinal toxicity demonstrated on multifocal ERG after 2 years 1
• Beneficial effects persist after discontinuation 1
• Less rebound effect with lower concentrations (0.01% vs 0.5%) 1

Contraindications and Precautions

Do not use in:

• Children under 3 months of age 6
• Known hypersensitivity to atropine 6
• Down syndrome, spastic paralysis, or brain damage (increased CNS toxicity risk) 6

Use cautiously in:

• Children under 3 years (limit to one drop per eye per day) 6
• Patients on MAO inhibitors (hypertensive crisis risk) 6

Comparative Effectiveness

Atropine ranks highest among all myopia control interventions 1:

• Network meta-analysis: muscarinic antagonists most effective, followed by specialty contact lenses 1
• Cochrane analysis: antimuscarinic agents show largest positive impact 1
• Superior to multifocal spectacles, which show only modest first-year effects 1

Practical Implementation

Counseling points:

• Daily compliance is essential (consider electronic monitoring if available) 3
• Photophobia typically mild but may require sunglasses outdoors 1
• Near vision usually unaffected at 0.01-0.05% concentrations 1
• Treatment should continue through active growth years 1

When to escalate concentration:

• If progression continues at >0.50 D/year on 0.01%, consider increasing to 0.025% or 0.05% 2
• Monitor for convergence issues when escalating dose 5

When to discontinue:

• Myopia stabilization (typically late adolescence)
• Development of strabismus or significant binocular dysfunction 5
• Intolerable side effects despite dose adjustment

This evidence-based approach prioritizes the 2023 AAO Preferred Practice Pattern guidelines [1-1], augmented by the most recent high-quality trials including the 2026 UK CHAMP study 3 and real-world effectiveness data 2.